Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coversin in PNH with Eculizumab Resistance
NCT02591862Phase 2Completed
- Sponsor
- Akari Therapeutics
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nomacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Akari Therapeutics. Primary endpoints: Ratio of LDH to the Upper Limit of Normal (ULN) at Day 28 and Number and Type of Adverse Events at 2 years. Started Feb 2016; status: completed.
02
Drugs
nomacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02591862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591862.